Adaptive Biotechnologies (ADPT) Non-Current Deffered Revenue (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Non-Current Deffered Revenue data on file, last reported at $807000.0 in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 96.75% year-over-year to $807000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $807000.0 (down 96.75% YoY) and the FY2025 annual result came in at $1.0 million, down 96.31% from the prior year.
• Non-Current Deffered Revenue retreated to $807000.0 in Q1 2026 per ADPT's latest filing, from $1.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $84.9 million in Q1 2022, with the low at $807000.0 in Q1 2026.
• Average Non-Current Deffered Revenue over 5 years is $39.4 million, with a median of $44.2 million recorded in 2024.
• Year-over-year, Non-Current Deffered Revenue slipped 18.08% in 2024 and sank 96.75% in 2026.
• Adaptive Biotechnologies' Non-Current Deffered Revenue stood at $58.6 million in 2022, then dropped by 23.56% to $44.8 million in 2023, then tumbled by 39.15% to $27.3 million in 2024, then sank by 96.31% to $1.0 million in 2025, then declined by 19.78% to $807000.0 in 2026.
• Business Quant data shows ADPT's Non-Current Deffered Revenue at $807000.0 in Q1 2026, $1.0 million in Q4 2025, and $1.2 million in Q3 2025.